{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T01:05:24Z","timestamp":1786755924399,"version":"build-2736575974"},"reference-count":54,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1248\/bpb.b20-00325","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T22:13:27Z","timestamp":1601504007000},"page":"1526-1533","source":"Crossref","is-referenced-by-count":12,"title":["Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells"],"prefix":"10.1248","volume":"43","author":[{"given":"Xin-Yi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis, School of pharmacology, China Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Bin","family":"Sun","sequence":"additional","affiliation":[{"name":"Nanjing Syrois Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, School of pharmacology, China Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Foley SB, Hildenbrand ZL, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI, Ross TS. Expression of BCR\/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Reports<\/i>, 5<\/b>, 51\u201360 (2013).","DOI":"10.1016\/j.celrep.2013.08.037"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chen M, Gallipoli P, DeGeer D, et al.<\/i> Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J. Natl. Cancer Inst.<\/i>, 105<\/b>, 405\u2013423 (2013).","DOI":"10.1093\/jnci\/djt006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science<\/i>, 247<\/b>, 824\u2013830 (1990).","DOI":"10.1126\/science.2406902"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia<\/i>, 16<\/b>, 2190\u20132196 (2002).","DOI":"10.1038\/sj.leu.2402741"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett.<\/i>, 274<\/b>, 1\u20139 (2009).","DOI":"10.1016\/j.canlet.2008.06.003"},{"key":"6","unstructured":"6) Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.<\/i>, 8<\/b>, 1018\u20131029 (2007)."},{"key":"7","unstructured":"7) Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.<\/i>, 8<\/b>, 1116\u20131128 (2007)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro<\/i> activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res.<\/i>, 65<\/b>, 4500\u20134505 (2005).","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus<\/i> imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.<\/i>, 362<\/b>, 2251\u20132259 (2010).","DOI":"10.1056\/NEJMoa0912614"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and ef\ufb01cacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood<\/i>, 118<\/b>, 4567\u20134576 (2011).","DOI":"10.1182\/blood-2011-05-355594"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene ampli\ufb01cation. Blood<\/i>, 95<\/b>, 1758\u20131766 (2000).","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or ampli\ufb01cation. Science<\/i>, 293<\/b>, 876\u2013880 (2001).","DOI":"10.1126\/science.1062538"},{"key":"13","unstructured":"13) Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk. Lymphoma<\/i>, 52<\/b>, 2139\u20132147 (2011)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder LJ, Keating A, Negrin SR, Weissman LI, Jamieson HMC. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 106<\/b>, 3925\u20133929 (2009).","DOI":"10.1073\/pnas.0900189106"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Eide CA, Zabriskie MS, SavageStevens SL, et al.<\/i> Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell<\/i>, 36<\/b>, 431\u2013443.e5 (2019).","DOI":"10.1016\/j.ccell.2019.08.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. Curr. Top. Med. Chem.<\/i>, 12<\/b>, 1356\u20131362 (2012).","DOI":"10.2174\/156802612801319034"},{"key":"17","unstructured":"17) Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med. Res. Rev.<\/i>, 27<\/b>, 591\u2013608 (2007)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Alisi A, Pastore A, Ceccarelli S, Panera N, Gnani D, Bruscalupi G, Massimi M, Tozzi G, Piemonte F, Nobili V. Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. Int. J. Mol. Sci.<\/i>, 13<\/b>, 2276\u20132289 (2012).","DOI":"10.3390\/ijms13022276"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Wu ZX, Yu BP, Xu L, Xia H. Emodin inhibits voltage-dependent potassium current in guinea pig gallbladder smooth muscle. Basic Clin. Pharmacol. Toxicol.<\/i>, 105<\/b>, 167\u2013172 (2009).","DOI":"10.1111\/j.1742-7843.2009.00419.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Lee YS, Kang OH, Choi JG, Oh YC, Keum JH, Kim SB, Jeong GS, Kim YC, Shin DW, Kwon DY. Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. Pharm. Biol.<\/i>, 48<\/b>, 1285\u20131290 (2010).","DOI":"10.3109\/13880201003770150"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ha MK, Song YH, Jeong SJ, Lee HJ, Jung JH, Kim B, Song HS, Huh JE, Kim SH. Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol. Pharm. Bull.<\/i>, 34<\/b>, 1432\u20131437 (2011).","DOI":"10.1248\/bpb.34.1432"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Heo SK, Yun HJ, Park WH, Park SD. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via<\/i> caspase- and mitochondrial-dependent apoptosis. J. Cell. Biochem.<\/i>, 105<\/b>, 70\u201380 (2008).","DOI":"10.1002\/jcb.21805"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lu Y, Yang JH, Li X, Hwangbo K, Hwang SL, Taketomi Y, Murakami M, Chang YC, Kim CH, Son JK, Chang HW. Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochem. Pharmacol.<\/i>, 82<\/b>, 1700\u20131708 (2011).","DOI":"10.1016\/j.bcp.2011.08.022"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Huang Z, Chen G, Shi P. Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. Arch. Pharm. Res.<\/i>, 31<\/b>, 742\u2013748 (2008).","DOI":"10.1007\/s12272-001-1221-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol. Cell. Biochem.<\/i>, 382<\/b>, 103\u2013111 (2013).","DOI":"10.1007\/s11010-013-1723-6"},{"key":"26","unstructured":"26) Liu A, Chen H, Wei W, Ye S, Liao W, Gong J, Jiang Z, Wang L, Lin S. Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol. Rep.<\/i>, 26<\/b>, 81\u201389 (2011). https:\/\/www.spandidos-publications.com\/10.3892\/or.2011.1257."},{"key":"27","unstructured":"27) Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via<\/i> downregulation of the expression of XIAP in vitro<\/i> and in vivo.<\/i> Int. J. Oncol.<\/i>, 39<\/b>, 1123\u20131131 (2011). https:\/\/www.spandidos-publications.com\/ijo\/39\/5\/1123."},{"key":"28","unstructured":"28) Hsu CM, Hsu YA, Tsai Y, Shieh FK, Huang SH, Wan L, Tsai FJ. Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. Biochem. Biophys. Res. Commun.<\/i>, 392<\/b>, 473\u2013478 (2010)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Yu JQ, Bao W, Lei JC. Emodin regulates apoptotic pathway in human liver cancer cells. Phytother. Res.<\/i>, 27<\/b>, 251\u2013257 (2013).","DOI":"10.1002\/ptr.4703"},{"key":"30","unstructured":"30) Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS, Yi J. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol. Ther.<\/i>, 7<\/b>, 468\u2013475 (2008)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chen P, Liu Y, Sun Y, Chen C, Qi Y, Zhang Y. AZT and emodin exhibit synergistic growth-inhibitory effects on K562\/ADM cells by inducing S phase cell cycle arrest and suppressing MDR1 mRNA\/p-gp protein expression. Pharm. Biol.<\/i>, 51<\/b>, 1586\u20131591 (2013).","DOI":"10.3109\/13880209.2013.803257"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Min H, Niu M, Zhang W, Yan J, Li J, Tan X, Li B, Su MX, Di B, Yan F. Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein. PLOS ONE<\/i>, 12<\/b>, e0187971 (2017).","DOI":"10.1371\/journal.pone.0187971"},{"key":"33","unstructured":"33) Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ. Establishment of an imatinib resistant cell line K562\/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi<\/i>, 25<\/b>, 337\u2013341 (2004). http:\/\/rs.yiigle.com\/zhxyxzz20042506\/397394.htm."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Wang WR, Zhang JF, Li YX, Yang XF, He YH, Li TT, Ren F, Zhang JY, Lin R. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1. Cancer Lett.<\/i>, 356<\/b> (2 Pt B), 791\u2013799 (2015).","DOI":"10.1016\/j.canlet.2014.10.033"},{"key":"35","unstructured":"35) Wang XF, Ge JB, Wang KQ, Qian JY. Effects of emodin on fluorescence analysis. Fudan Univ. J. Med. Sci.<\/i>, 33<\/b>, 262\u2013265 (2006)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Wylie AA, Schoepfer J, Jahnke W, et al.<\/i> The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature<\/i>, 543<\/b>, 733\u2013737 (2017).","DOI":"10.1038\/nature21702"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood<\/i>, 117<\/b>, 3421\u20133429 (2011).","DOI":"10.1182\/blood-2009-11-255232"},{"key":"38","unstructured":"38) Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica<\/i>, 102<\/b>, 1519\u20131529 (2017)."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer<\/i>, 5<\/b>, 172\u2013183 (2005).","DOI":"10.1038\/nrc1567"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res.<\/i>, 68<\/b>, 9624\u20139633 (2008).","DOI":"10.1158\/0008-5472.CAN-08-1131"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Li S. Src kinase signaling in leukaemia. Int. J. Biochem. Cell Biol.<\/i>, 39<\/b>, 1483\u20131488 (2007).","DOI":"10.1016\/j.biocel.2007.01.027"},{"key":"42","unstructured":"42) Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol.<\/i>, 28<\/b> (Suppl. 17), 9\u201318 (2001)."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J. Clin. Oncol.<\/i>, 34<\/b>, 2851\u20132857 (2016).","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Gambacorti-Passerini C, Antolini L, Mahon FX, et al.<\/i> Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst.<\/i>, 103<\/b>, 553\u2013561 (2011).","DOI":"10.1093\/jnci\/djr060"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia<\/i>, 21<\/b>, 926\u2013935 (2007).","DOI":"10.1038\/sj.leu.2404609"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Casetti L, Martin-Lanneree S, Najjar I, Plo I, Auge S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem\/progenitor cells. Cancer Res.<\/i>, 73<\/b>, 2052\u20132058 (2013).","DOI":"10.1158\/0008-5472.CAN-12-3955"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras IZ, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia<\/i>, 28<\/b>, 629\u2013641 (2014).","DOI":"10.1038\/leu.2013.351"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H, Muller-Newen G. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells. Oncogene<\/i>, 32<\/b>, 3587\u20133597 (2013).","DOI":"10.1038\/onc.2012.369"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell<\/i>, 12<\/b>, 66\u201380 (2007).","DOI":"10.1016\/j.ccr.2007.05.006"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Abraham SA, Hopcroft LEM, Carrick E, Drotar ME, Dunn K, Williamson AJK, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature<\/i>, 534<\/b>, 341\u2013346 (2016).","DOI":"10.1038\/nature18288"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell Biol.<\/i>, 9<\/b>, 932\u2013944 (2007).","DOI":"10.1038\/ncb1618"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene<\/i>, 21<\/b>, 8075\u20138088 (2002).","DOI":"10.1038\/sj.onc.1206008"},{"key":"53","unstructured":"53) Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J. Hematol. Oncol.<\/i>, 11<\/b>, 84 (2018)."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Deng X, Okram B, Ding Q, Zhang J, Choi Y, Adrian FJ, Wojciechowski A, Zhang G, Che J, Bursulaya B, Cowan-Jacob SW, Rummel G, Sim T, Gray NS. Expanding the diversity of allosteric bcr-abl inhibitors. J. Med. Chem.<\/i>, 53<\/b>, 6934\u20136946 (2010).","DOI":"10.1021\/jm100555f"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/10\/43_b20-00325\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T12:12:30Z","timestamp":1669032750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/10\/43_b20-00325\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00325","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}